CoChat
Sign Up
Cited by 73

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Myelin lipid metabolism and its role in myelination and myelin maintenance

Barnes-Vélez, Joseph A., Aksoy Yasar, Fatma Betul, Hu, Jian·2023·The Innovation
DOI 10.1016/j.xinn.2022.100360PMC PMC9800635
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xinn.2022.100360

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Representative images of myelinated fibers and myelin sheath from mouse nerve (A) Left: transmission electron micrograph of myelinated and non-myelinated nerve fibers from cross-sectioned mouse sciatic nerve. Right: pseudo-colored overlay of the electron micrograph on the left. Red regions denote the myelin sheath, and yellow regions represent axon fibers. (B) High-magnification micrograph of mouse sciatic nerve to illustrate the multiple layers of myelin membrane that together compose the myelin sheath. (C) Pie chart delineating myelin lipid composition as molar percentage of total lipids as reported for bovine myelin from the CNS.11,12 Chol, cholesterol; Galc, galactocerebrosides; Sulf, sulfatides; Plas, plasmalogens; PC, phosphatidylcholine phospholipids; SM, sphingomyelin.
Figure 1 Representative images of myelinated fibers and myelin sheath from mouse nerve (A) Left: transmission electron micrograph of myelinated and non-myelinated nerve fibers from cross-sectioned mouse sciatic nerve. Right: pseudo-colored overlay of the electron micrograph on the left. Red regions denote the myelin sheath, and yellow regions represent axon fibers. (B) High-magnification micrograph of mouse sciatic nerve to illustrate the multiple layers of myelin membrane that together compose the myelin sheath. (C) Pie chart delineating myelin lipid composition as molar percentage of total lipids as reported for bovine myelin from the CNS.11,12 Chol, cholesterol; Galc, galactocerebrosides; Sulf, sulfatides; Plas, plasmalogens; PC, phosphatidylcholine phospholipids; SM, sphingomyelin.CC BY-NC-ND · PubMed Central
Figure 2 Cholesterol, sterol-response-element-binding protein (SREBP), and mammalian target of rapamycin (mTOR) pathways necessary in myelination (A) Farnesyl-diphosphate farnesyltransferase 1 (FDFT1) synthesizes squalene, a key intermediate in cholesterol synthesis. (B) Low-density lipoprotein receptor-related protein 1 (LRP1) enables endocytosis of lipoprotein particles, which deliver exogenous cholesterol. (C) Sterol cleavage-activating protein (SCAP), in response to decreased ER cholesterol, shuttles the SREBPs to the Golgi apparatus for cleavage-mediated activation by site-1 and site-2 proteases (S1P and S2P). (D) Elevated ER cholesterol induces SCAP to associate with and be inhibited by insulin-induced gene protein (Insig), reducing SCAP-mediated SREBP2 activation. (E) Quaking (QKI) is a critical co-activator for SREBP2 in OLs that is necessary for transcription of cholesterol-synthesizing genes. (F) mTOR, regulatory-associated protein of mTOR (Raptor), and mTOR-associated protein, LST8 homolog (mLst8) are subunits of the mTORC1 complex that increase SREBP activity through multiple mechanisms. One reported mechanism includes inhibiting the flux of autophagolysosome-derived cholesterol to the ER and preventing cholesterol-mediated inhibition on SREBP activation. OL, oligodendrocyte.
Figure 2 Cholesterol, sterol-response-element-binding protein (SREBP), and mammalian target of rapamycin (mTOR) pathways necessary in myelination (A) Farnesyl-diphosphate farnesyltransferase 1 (FDFT1) synthesizes squalene, a key intermediate in cholesterol synthesis. (B) Low-density lipoprotein receptor-related protein 1 (LRP1) enables endocytosis of lipoprotein particles, which deliver exogenous cholesterol. (C) Sterol cleavage-activating protein (SCAP), in response to decreased ER cholesterol, shuttles the SREBPs to the Golgi apparatus for cleavage-mediated activation by site-1 and site-2 proteases (S1P and S2P). (D) Elevated ER cholesterol induces SCAP to associate with and be inhibited by insulin-induced gene protein (Insig), reducing SCAP-mediated SREBP2 activation. (E) Quaking (QKI) is a critical co-activator for SREBP2 in OLs that is necessary for transcription of cholesterol-synthesizing genes. (F) mTOR, regulatory-associated protein of mTOR (Raptor), and mTOR-associated protein, LST8 homolog (mLst8) are subunits of the mTORC1 complex that increase SREBP activity through multiple mechanisms. One reported mechanism includes inhibiting the flux of autophagolysosome-derived cholesterol to the ER and preventing cholesterol-mediated inhibition on SREBP activation. OL, oligodendrocyte.CC BY-NC-ND · PubMed Central
Figure 3 Fatty acid, galactocerebroside, and sulfatide synthesis pathways implicated in myelination and myelin maintenance (A) Condensation of serine and palmitoyl-CoA by serine palmitoyltransferase (SPT) initiates Cer synthesis, which is then completed through the activity of ceramide synthase (Cers) and dihydroceramide desaturase (DEGS). (B) Ceramide galactosyl-transferase (CGT)-mediated addition of galactose to Cer generates GalC. Following translocation to the Golgi, addition of sulfate to GalC by cerebroside sulfotransferase (CST) forms Sulf. Conversely, Cer taken to the Golgi can be glycosylated to GlcC by UDP-glucose ceramide glucosyltransferase (UGCG), which can be further glycosylated into complex glycosphingolipids including globosides and gangliosides. (C) Fatty acid 2-hydroxylase (FA2H) catalyzes FA hydroxylation. Hydroxylated FA (2OH-FA) are used as substrates by sphingolipid-synthesizing enzymes to generate hydroxylated sphingolipids. (D) The rich heterogeneity of sphingolipids stems from the multiple species of FA used as substrates for dihydrosphingosine acylation, including saturated (SFA), monounsaturated (MUFA), and polyunsaturated (PUFA) FA. Elongation of endogenous or diet-derived FA requires fatty acid elongases (ELOVL) and hydroxyacyl dehydratases (HACD). FA desaturation depends on FA desaturases, including FADS and SCD. (E) Fatty acid synthase (FASN) generates palmitate, a principal source for endogenous SFA and MUFA. (F) The nuclear receptors peroxisome proliferator-activated receptor β (PPARβ) and retinoic X receptor α (RXRα), following co-activation by quaking (QKI), drive transcription of the FA biosynthesis pathway. FA, fatty acid; Cer, ceramide; GalC, galactocerebroside; Sulf, sulfatides; GlcC, glucocerebroside.
Figure 3 Fatty acid, galactocerebroside, and sulfatide synthesis pathways implicated in myelination and myelin maintenance (A) Condensation of serine and palmitoyl-CoA by serine palmitoyltransferase (SPT) initiates Cer synthesis, which is then completed through the activity of ceramide synthase (Cers) and dihydroceramide desaturase (DEGS). (B) Ceramide galactosyl-transferase (CGT)-mediated addition of galactose to Cer generates GalC. Following translocation to the Golgi, addition of sulfate to GalC by cerebroside sulfotransferase (CST) forms Sulf. Conversely, Cer taken to the Golgi can be glycosylated to GlcC by UDP-glucose ceramide glucosyltransferase (UGCG), which can be further glycosylated into complex glycosphingolipids including globosides and gangliosides. (C) Fatty acid 2-hydroxylase (FA2H) catalyzes FA hydroxylation. Hydroxylated FA (2OH-FA) are used as substrates by sphingolipid-synthesizing enzymes to generate hydroxylated sphingolipids. (D) The rich heterogeneity of sphingolipids stems from the multiple species of FA used as substrates for dihydrosphingosine acylation, including saturated (SFA), monounsaturated (MUFA), and polyunsaturated (PUFA) FA. Elongation of endogenous or diet-derived FA requires fatty acid elongases (ELOVL) and hydroxyacyl dehydratases (HACD). FA desaturation depends on FA desaturases, including FADS and SCD. (E) Fatty acid synthase (FASN) generates palmitate, a principal source for endogenous SFA and MUFA. (F) The nuclear receptors peroxisome proliferator-activated receptor β (PPARβ) and retinoic X receptor α (RXRα), following co-activation by quaking (QKI), drive transcription of the FA biosynthesis pathway. FA, fatty acid; Cer, ceramide; GalC, galactocerebroside; Sulf, sulfatides; GlcC, glucocerebroside.CC BY-NC-ND · PubMed Central
Figure 4 Elements of peroxisome, plasmalogen, and phospholipid metabolism required for myelin integrity (A) Oxidation of very-long-chain fatty acids (VLCFAs) occurs within peroxisomes. VLC-acyl-CoA are imported by ATP-binding cassette transporter subfamily D (ABCD) transporters, principally ABCD1. VLC-acyl-CoA are then oxidized into shorter-chain acyl-CoA by a series of reactions requiring acyl-CoA oxidase (ACOX1), 17-β-hydroxysteroid dehydrogenase IV (HSD17B4), and sterol carrier protein 2 (SCP2). (B) Initial steps for plasmalogen synthesis require peroxisomal enzymes. Glycerone phosphate-O-acyltransferase (GNPAT) synthesizes 1-acyl-DHAP, which is converted to 1-alkyl-O-DHAP by alkylglycerone phosphate synthase (AGPS). 1-Alkyl-O-DHAP is reduced by alkyl DHAP reductase (ADR) to alkyl-G3P, which passes to the ER to complete plasmalogen synthesis. (C) Peroxisome matrix proteins, including AGPS, require carrier proteins, such as PEX7 and the PEX5L isoform, to enter peroxisomes. (D) Fatty alcohols derived from fatty acyl-CoA reductase 1 (FAR1) are utilized for plasmalogen synthesis. (E) Most plasmalogens in myelin exist as phosphatidylethanolamine lipids (PE-plasmalogens). Ethanolamine (Etn) is phosphorylated by ethanolamine kinase (EK) and coupled with CDP by ethanolamine phosphate cytidylyltransferase (PCYT2). Selenoprotein I (SELENOI) converts 1-O-alkyl-2-acylglycerol (AAG) into 1-O-alkyl-2-acyl-GPE (AA-PE) using PCYT2-derived CDP-Etn. AA-PE is then converted to PE-plasmalogen by plasmanylethanolamine desaturase (PEDS). (F) Balance of fatty acids and fatty alcohols is maintained in part by members of the aldehyde dehydrogenase (ALDH) family, including ALDH3A2. CDP, cytidine diphosphate; DHAP, dihydroxyacetone phosphate; ACSVL, very-long-chain acyl-CoA-synthase; ACS, acyl-CoA synthase.
Figure 4 Elements of peroxisome, plasmalogen, and phospholipid metabolism required for myelin integrity (A) Oxidation of very-long-chain fatty acids (VLCFAs) occurs within peroxisomes. VLC-acyl-CoA are imported by ATP-binding cassette transporter subfamily D (ABCD) transporters, principally ABCD1. VLC-acyl-CoA are then oxidized into shorter-chain acyl-CoA by a series of reactions requiring acyl-CoA oxidase (ACOX1), 17-β-hydroxysteroid dehydrogenase IV (HSD17B4), and sterol carrier protein 2 (SCP2). (B) Initial steps for plasmalogen synthesis require peroxisomal enzymes. Glycerone phosphate-O-acyltransferase (GNPAT) synthesizes 1-acyl-DHAP, which is converted to 1-alkyl-O-DHAP by alkylglycerone phosphate synthase (AGPS). 1-Alkyl-O-DHAP is reduced by alkyl DHAP reductase (ADR) to alkyl-G3P, which passes to the ER to complete plasmalogen synthesis. (C) Peroxisome matrix proteins, including AGPS, require carrier proteins, such as PEX7 and the PEX5L isoform, to enter peroxisomes. (D) Fatty alcohols derived from fatty acyl-CoA reductase 1 (FAR1) are utilized for plasmalogen synthesis. (E) Most plasmalogens in myelin exist as phosphatidylethanolamine lipids (PE-plasmalogens). Ethanolamine (Etn) is phosphorylated by ethanolamine kinase (EK) and coupled with CDP by ethanolamine phosphate cytidylyltransferase (PCYT2). Selenoprotein I (SELENOI) converts 1-O-alkyl-2-acylglycerol (AAG) into 1-O-alkyl-2-acyl-GPE (AA-PE) using PCYT2-derived CDP-Etn. AA-PE is then converted to PE-plasmalogen by plasmanylethanolamine desaturase (PEDS). (F) Balance of fatty acids and fatty alcohols is maintained in part by members of the aldehyde dehydrogenase (ALDH) family, including ALDH3A2. CDP, cytidine diphosphate; DHAP, dihydroxyacetone phosphate; ACSVL, very-long-chain acyl-CoA-synthase; ACS, acyl-CoA synthase.CC BY-NC-ND · PubMed Central
Figure 5 Myelin disruption in leukodystrophies and Alzheimer’s disease (A) Leukodystrophy-associated lipid dysregulation occurs from mutations in genes that contribute to lipid synthesis or catabolism (see Table 1). (B) With aging, there is a decline with brain lipids enriched in myelin and a decrease in myelin renewal. (C) APP/PS1 mice experience demyelination, which exacerbates AD-like memory deficits. Clemastine treatment or conditional knockout (cKO) of M1R in OPCs restored myelin renewal and ameliorated cognitive decline.207
Figure 5 Myelin disruption in leukodystrophies and Alzheimer’s disease (A) Leukodystrophy-associated lipid dysregulation occurs from mutations in genes that contribute to lipid synthesis or catabolism (see Table 1). (B) With aging, there is a decline with brain lipids enriched in myelin and a decrease in myelin renewal. (C) APP/PS1 mice experience demyelination, which exacerbates AD-like memory deficits. Clemastine treatment or conditional knockout (cKO) of M1R in OPCs restored myelin renewal and ameliorated cognitive decline.207CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 204

  1. Tasaki, 1939, The electro-saltatory transmission of the nerve impulse and the effect of narcosis upon the nerve fiber, American Journal of Physiology-Legacy Content, 127, 211, 10.1152/ajplegacy.1939.127.2.211 · DOI
  2. Huxley, 1949, Evidence for saltatory conduction in peripheral myelinated nerve fibres, J. Physiol., 108, 315, 10.1113/jphysiol.1949.sp004335 · DOI
  3. Pease-Raissi, 2021, Building a (w)rapport between neurons and oligodendroglia: reciprocal interactions underlying adaptive myelination, Neuron, 109, 1258, 10.1016/j.neuron.2021.02.003 · DOI
  4. Harty, 2017, Unwrapping the unappreciated: recent progress in Remak Schwann cell biology, Curr. Opin. Neurobiol., 47, 131, 10.1016/j.conb.2017.10.003 · DOI
  5. Stierli, 2019, Schwann cell plasticity-roles in tissue homeostasis, regeneration, and disease, Glia, 67, 2203, 10.1002/glia.23643 · DOI
  6. Stierli, 2018, The regulation of the homeostasis and regeneration of peripheral nerve is distinct from the CNS and independent of a stem cell population, Development, 145, dev170316, 10.1242/dev.170316 · DOI
  7. Norton, 1973, Myelination in rat brain: changes in myelin composition during brain maturation, J. Neurochem., 21, 759, 10.1111/j.1471-4159.1973.tb07520.x · DOI
  8. O'Brien, 1965, Lipid composition of the normal human brain: gray matter, white matter, and myelin, J. Lipid Res., 6, 537, 10.1016/S0022-2275(20)39619-X · DOI · Paper page
  9. O'Brien, 1967, Lipid composition of myelin from the peripheral nervous system. Intradural spinal roots, J. Neurochem., 14, 357, 10.1111/j.1471-4159.1967.tb09532.x · DOI
  10. Schmitt, 2015, Metabolism and functions of lipids in myelin, Biochim. Biophys. Acta, 1851, 999, 10.1016/j.bbalip.2014.12.016 · DOI
  11. Lingwood, 2010, Lipid rafts as a membrane-organizing principle, Science, 327, 46, 10.1126/science.1174621 · DOI · Paper page
  12. Korade, 2008, Lipid rafts, cholesterol, and the brain, Neuropharmacology, 55, 1265, 10.1016/j.neuropharm.2008.02.019 · DOI · Paper page
  13. Saher, 2011, Cholesterol: a novel regulatory role in myelin formation, Neuroscientist, 17, 79, 10.1177/1073858410373835 · DOI · Paper page
  14. Woelk, 1973, Lipid and fatty acid composition of myelin purified from normal and MS brains, Eur. Neurol., 10, 250, 10.1159/000114281 · DOI
  15. Yang, 2016, The role of cholesterol in membrane fusion, Chem. Phys. Lipids, 199, 136, 10.1016/j.chemphyslip.2016.05.003 · DOI · Paper page
  16. Saher, 2010, Cholesterol and myelin biogenesis, Subcell. Biochem., 51, 489, 10.1007/978-90-481-8622-8_18 · DOI
  17. Saher, 2009, Cholesterol regulates the endoplasmic reticulum exit of the major membrane protein P0 required for peripheral myelin compaction, J. Neurosci., 29, 6094, 10.1523/JNEUROSCI.0686-09.2009 · DOI
  18. Saher, 2015, Cholesterol in myelin biogenesis and hypomyelinating disorders, Biochim. Biophys. Acta, 1851, 1083, 10.1016/j.bbalip.2015.02.010 · DOI · Paper page
  19. Klugmann, 1997, Assembly of CNS myelin in the absence of proteolipid protein, Neuron, 18, 59, 10.1016/S0896-6273(01)80046-5 · DOI
  20. Werner, 2013, A critical role for the cholesterol-associated proteolipids PLP and M6B in myelination of the central nervous system, Glia, 61, 567, 10.1002/glia.22456 · DOI
  21. Zhou, 2019, PMP22 regulates cholesterol trafficking and ABCA1-mediated cholesterol efflux, J. Neurosci., 39, 5404, 10.1523/JNEUROSCI.2942-18.2019 · DOI
  22. Miron, 2009, Statin therapy inhibits remyelination in the central nervous system, Am. J. Pathol., 174, 1880, 10.2353/ajpath.2009.080947 · DOI · Paper page
  23. Camargo, 2009, SREBPs: SREBP function in glia-neuron interactions, FEBS J., 276, 628, 10.1111/j.1742-4658.2008.06808.x · DOI
  24. Verheijen, 2003, Local regulation of fat metabolism in peripheral nerves, Genes Dev., 17, 2450, 10.1101/gad.1116203 · DOI · Paper page
  25. Leblanc, 2005, Regulation of cholesterol/lipid biosynthetic genes by Egr2/Krox20 during peripheral nerve myelination, J. Neurochem., 93, 737, 10.1111/j.1471-4159.2005.03056.x · DOI
  26. Suzuki, 2013, Reduction of the cholesterol sensor SCAP in the brains of mice causes impaired synaptic transmission and altered cognitive function, PLoS Biol., 11, 10.1371/journal.pbio.1001532 · DOI
  27. Verheijen, 2009, SCAP is required for timely and proper myelin membrane synthesis, Proc. Natl. Acad. Sci. USA, 106, 21383, 10.1073/pnas.0905633106 · DOI · Paper page
  28. Camargo, 2012, High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism, Faseb. J., 26, 4302, 10.1096/fj.12-205807 · DOI
  29. Wattenberg, 2019, Intra- and intercellular trafficking in sphingolipid metabolism in myelination, Adv. Biol. Regul., 71, 97, 10.1016/j.jbior.2018.11.002 · DOI
  30. Yamaji, 2015, Sphingolipid metabolism and interorganellar transport: localization of sphingolipid enzymes and lipid transfer proteins, Traffic, 16, 101, 10.1111/tra.12239 · DOI
  31. O'Brien, 1964, The fatty acid composition of brain sphingolipids: sphingomyelin, ceramide, cerebroside, and cerebroside sulfate, J. Lipid Res., 5, 339, 10.1016/S0022-2275(20)40202-0 · DOI
  32. Bakhti, 2014, Myelin architecture: zippering membranes tightly together, Cell. Mol. Life Sci., 71, 1265, 10.1007/s00018-013-1492-0 · DOI
  33. Boggs, 2010, Participation of galactosylceramide and sulfatide in glycosynapses between oligodendrocyte or myelin membranes, FEBS Lett., 584, 1771, 10.1016/j.febslet.2009.11.074 · DOI
  34. Grassi, 2016, The role of 3-O-sulfogalactosylceramide, sulfatide, in the lateral organization of myelin membrane, Neurochem. Res., 41, 130, 10.1007/s11064-015-1747-2 · DOI
  35. Kulkarni, 1999, Adhesion between cerebroside bilayers, Biochemistry, 38, 15264, 10.1021/bi991725m · DOI
  36. Bosio, 1996, Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis, Proc. Natl. Acad. Sci. USA, 93, 13280, 10.1073/pnas.93.23.13280 · DOI
  37. Coetzee, 1996, Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability, Cell, 86, 209, 10.1016/S0092-8674(00)80093-8 · DOI
  38. Marcus, 2006, Sulfatide is essential for the maintenance of CNS myelin and axon structure, Glia, 53, 372, 10.1002/glia.20292 · DOI
  39. Dupree, 1998, Myelin abnormalities in mice deficient in galactocerebroside and sulfatide, J. Neurocytol., 27, 649, 10.1023/A:1006908013972 · DOI
  40. Honke, 2002, Paranodal junction formation and spermatogenesis require sulfoglycolipids, Proc. Natl. Acad. Sci. USA, 99, 4227, 10.1073/pnas.032068299 · DOI
  41. Ishibashi, 2002, A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation, J. Neurosci., 22, 6507, 10.1523/JNEUROSCI.22-15-06507.2002 · DOI
  42. Hayashi, 2013, Sulfatide decrease in myelin influences formation of the paranodal axo-glial junction and conduction velocity in the sciatic nerve, Glia, 61, 466, 10.1002/glia.22447 · DOI
  43. Ozgen, 2014, The lateral membrane organization and dynamics of myelin proteins PLP and MBP are dictated by distinct galactolipids and the extracellular matrix, PLoS One, 9, 10.1371/journal.pone.0101834 · DOI
  44. Palavicini, 2016, Novel molecular insights into the critical role of sulfatide in myelin maintenance/function, J. Neurochem., 139, 40, 10.1111/jnc.13738 · DOI
  45. Pomicter, 2013, Nfasc155H and MAG are specifically susceptible to detergent extraction in the absence of the myelin sphingolipid sulfatide, Neurochem. Res., 38, 2490, 10.1007/s11064-013-1162-5 · DOI
  46. Suzuki, 2004, Paranodal axoglial junction is required for the maintenance of the Nav1.6-type sodium channel in the node of Ranvier in the optic nerves but not in peripheral nerve fibers in the sulfatide-deficient mice, Glia, 46, 274, 10.1002/glia.20008 · DOI
  47. Suzuki, 1999, Drastically abnormal gluco- and galactosylceramide composition does not affect ganglioside metabolism in the brain of mice deficient in galactosylceramide synthase, Neurochem. Res., 24, 471, 10.1023/A:1022571410445 · DOI
  48. Zöller, 2005, Oligodendrocyte-specific ceramide galactosyltransferase (CGT) expression phenotypically rescues CGT-deficient mice and demonstrates that CGT activity does not limit brain galactosylceramide level, Glia, 52, 190, 10.1002/glia.20230 · DOI
  49. Hama, 2010, Fatty acid 2-Hydroxylation in mammalian sphingolipid biology, Biochim. Biophys. Acta, 1801, 405, 10.1016/j.bbalip.2009.12.004 · DOI
  50. Alderson, 2006, FA2H-dependent fatty acid 2-hydroxylation in postnatal mouse brain, J. Lipid Res., 47, 2772, 10.1194/jlr.M600362-JLR200 · DOI
  51. Eckhardt, 2005, A mammalian fatty acid hydroxylase responsible for the formation of alpha-hydroxylated galactosylceramide in myelin, Biochem. J., 388, 245, 10.1042/BJ20041451 · DOI
  52. Maldonado, 2008, FA2H is responsible for the formation of 2-hydroxy galactolipids in peripheral nervous system myelin, J. Lipid Res., 49, 153, 10.1194/jlr.M700400-JLR200 · DOI
  53. Zöller, 2008, Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration, J. Neurosci., 28, 9741, 10.1523/JNEUROSCI.0458-08.2008 · DOI
  54. Potter, 2011, Central nervous system dysfunction in a mouse model of FA2H deficiency, Glia, 59, 1009, 10.1002/glia.21172 · DOI
  55. Saadat, 2010, Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice, Glia, 58, 391, 10.1002/glia.20930 · DOI · Paper page
  56. Meixner, 2011, Myelination in the absence of UDP-galactose:ceramide galactosyl-transferase and fatty acid 2 -hydroxylase, BMC Neurosci., 12, 22, 10.1186/1471-2202-12-22 · DOI
  57. Braverman, 2012, Functions of plasmalogen lipids in health and disease, Biochim. Biophys. Acta, 1822, 1442, 10.1016/j.bbadis.2012.05.008 · DOI · Paper page
  58. Nagan, 2001, Plasmalogens: biosynthesis and functions, Prog. Lipid Res., 40, 199, 10.1016/S0163-7827(01)00003-0 · DOI
  59. Rapport, 1959, The structure of plasmalogens. IV. Lipids in normal and neoplastic tissues of man and in normal tissues of rabbit and rat, Biochim. Biophys. Acta, 33, 319, 10.1016/0006-3002(59)90119-2 · DOI
  60. Heymans, 1983, Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome), Nature, 306, 69, 10.1038/306069a0 · DOI
  61. Webster, 1960, Studies on the plasmalogens of nervous tissue, Biochim. Biophys. Acta, 44, 109, 10.1016/0006-3002(60)91529-8 · DOI
  62. Balakrishnan, 1961, The distribution of phosphorus-containing lipid compounds in the human brain, J. Neurochem., 8, 276, 10.1111/j.1471-4159.1961.tb13553.x · DOI
  63. Norton, 1966, The lipid composition of purified bovine brain myelin, J. Neurochem., 13, 213, 10.1111/j.1471-4159.1966.tb06794.x · DOI
  64. Cumings, 1958, Lipids in the brains of infants and children, J. Neurochem., 2, 289, 10.1111/j.1471-4159.1958.tb12377.x · DOI
  65. Han, 1990, Plasmenylcholine and phosphatidylcholine membrane bilayers possess distinct conformational motifs, Biochemistry, 29, 4992, 10.1021/bi00472a032 · DOI
  66. Rubio, 2018, Regulation of phagocytosis in macrophages by membrane ethanolamine plasmalogens, Front. Immunol., 9, 1723, 10.3389/fimmu.2018.01723 · DOI
  67. Dean, 2018, Structural and functional roles of ether lipids, Protein Cell, 9, 196, 10.1007/s13238-017-0423-5 · DOI
  68. Luoma, 2015, Plasmalogen phospholipids protect internodal myelin from oxidative damage, Free Radic. Biol. Med., 84, 296, 10.1016/j.freeradbiomed.2015.03.012 · DOI · Paper page
  69. Sindelar, 1999, The protective role of plasmalogens in iron-induced lipid peroxidation, Free Radic. Biol. Med., 26, 318, 10.1016/S0891-5849(98)00221-4 · DOI
  70. Zou, 2020, Plasticity of ether lipids promotes ferroptosis susceptibility and evasion, Nature, 585, 603, 10.1038/s41586-020-2732-8 · DOI
  71. Gross, 1984, High plasmalogen and arachidonic acid content of canine myocardial sarcolemma: a fast atom bombardment mass spectroscopic and gas chromatography-mass spectroscopic characterization, Biochemistry, 23, 158, 10.1021/bi00296a026 · DOI
  72. da Silva, 2014, Peripheral nervous system plasmalogens regulate Schwann cell differentiation and myelination, J. Clin. Invest., 124, 2560, 10.1172/JCI72063 · DOI
  73. Malheiro, 2019, Leukodystrophy caused by plasmalogen deficiency rescued by glyceryl 1-myristyl ether treatment, Brain Pathol., 29, 622, 10.1111/bpa.12710 · DOI · Paper page
  74. Brites, 2003, Impaired neuronal migration and endochondral ossification in Pex7 knockout mice: a model for rhizomelic chondrodysplasia punctata, Hum. Mol. Genet., 12, 2255, 10.1093/hmg/ddg236 · DOI · Paper page
  75. Rodemer, 2003, Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice, Hum. Mol. Genet., 12, 1881, 10.1093/hmg/ddg191 · DOI
  76. Teigler, 2009, Defects in myelination, paranode organization and Purkinje cell innervation in the ether lipid-deficient mouse cerebellum, Hum. Mol. Genet., 18, 1897, 10.1093/hmg/ddp110 · DOI · Paper page
  77. Dorninger, 2015, Homeostasis of phospholipids - the level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens, Biochim. Biophys. Acta, 1851, 117, 10.1016/j.bbalip.2014.11.005 · DOI
  78. Hoxha, 2021, Elovl5 is required for proper action potential conduction along peripheral myelinated fibers, Glia, 69, 2419, 10.1002/glia.24048 · DOI
  79. Montani, 2018, De novo fatty acid synthesis by Schwann cells is essential for peripheral nervous system myelination, J. Cell Biol., 217, 1353, 10.1083/jcb.201706010 · DOI
  80. Dimas, 2019, CNS myelination and remyelination depend on fatty acid synthesis by oligodendrocytes, Elife, 8, 10.7554/eLife.44702 · DOI · Paper page
  81. Berger, 2002, The mechanisms of action of PPARs, Annu. Rev. Med., 53, 409, 10.1146/annurev.med.53.082901.104018 · DOI · Paper page
  82. Krey, 1993, Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids, J. Steroid Biochem. Mol. Biol., 47, 65, 10.1016/0960-0760(93)90058-5 · DOI
  83. Berger, 2002, Physiological and therapeutic roles of peroxisome proliferator-activated receptors, Diabetes Technol. Therapeut., 4, 163, 10.1089/15209150260007381 · DOI
  84. Mandrekar-Colucci, 2013, PPAR agonists as therapeutics for CNS trauma and neurological diseases, ASN Neuro, 5, 10.1042/AN20130030 · DOI
  85. Zolezzi, 2017, PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation, Biol. Rev. Camb. Phil. Soc., 92, 2046, 10.1111/brv.12320 · DOI
  86. Agarwal, 2017, Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders, Biochem. Biophys. Res. Commun., 483, 1166, 10.1016/j.bbrc.2016.08.043 · DOI
  87. Braissant, 1998, Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development, Endocrinology, 139, 2748, 10.1210/endo.139.6.6049 · DOI
  88. Granneman, 1998, Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes, J. Neurosci. Res., 51, 563, 10.1002/(SICI)1097-4547(19980301)51:5<563::AID-JNR3>3.0.CO;2-D · DOI
  89. Higashiyama, 2007, Expression profiling of liver receptor homologue 1 (LRH-1) in mouse tissues using tissue microarray, J. Mol. Histol., 38, 45, 10.1007/s10735-007-9077-6 · DOI
  90. Woods, 2003, Localization of PPARdelta in murine central nervous system: expression in oligodendrocytes and neurons, Brain Res., 975, 10, 10.1016/S0006-8993(03)02515-0 · DOI
  91. Saluja, 2001, PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture, Glia, 33, 191, 10.1002/1098-1136(200103)33:3<191::AID-GLIA1018>3.0.CO;2-M · DOI
  92. Jana, 2012, Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-beta, J. Biol. Chem., 287, 34134, 10.1074/jbc.M112.398552 · DOI
  93. Vittoria Simonini, 2010, Regulation of oligodendrocyte progenitor cell maturation by PPARdelta: effects on bone morphogenetic proteins, ASN Neuro, 2
  94. Almad, 2010, Chronic expression of PPAR-delta by oligodendrocyte lineage cells in the injured rat spinal cord, J. Comp. Neurol., 518, 785, 10.1002/cne.22242 · DOI
  95. Peters, 2000, Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta), Mol. Cell Biol., 20, 5119, 10.1128/MCB.20.14.5119-5128.2000 · DOI
  96. Zhou, 2020, Mature myelin maintenance requires Qki to coactivate PPARbeta-RXRalpha-mediated lipid metabolism, J. Clin. Invest., 130, 2220, 10.1172/JCI131800 · DOI
  97. Cermenati, 2015, Lack of sterol regulatory element binding factor-1c imposes glial Fatty Acid utilization leading to peripheral neuropathy, Cell Metabol., 21, 571, 10.1016/j.cmet.2015.02.016 · DOI
  98. DeBose-Boyd, 2018, SREBPs in lipid metabolism, insulin signaling, and beyond, Trends Biochem. Sci., 43, 358, 10.1016/j.tibs.2018.01.005 · DOI
  99. Monnerie, 2017, Reduced sterol regulatory element-binding protein (SREBP) processing through site-1 protease (S1P) inhibition alters oligodendrocyte differentiation in vitro, J. Neurochem., 140, 53, 10.1111/jnc.13721 · DOI
  100. Shin, 2021, Qki activates Srebp2-mediated cholesterol biosynthesis for maintenance of eye lens transparency, Nat. Commun., 12, 3005, 10.1038/s41467-021-22782-0 · DOI
  101. Zhou, 2021, Qki regulates myelinogenesis through Srebp2-dependent cholesterol biosynthesis, Elife, 10, e60467, 10.7554/eLife.60467 · DOI
  102. Eid, 2017, mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells, Proc. Natl. Acad. Sci. USA, 114, 7999, 10.1073/pnas.1705304114 · DOI
  103. Sherman, 2012, Arrest of myelination and reduced axon growth when Schwann cells lack mTOR, J. Neurosci., 32, 1817, 10.1523/JNEUROSCI.4814-11.2012 · DOI
  104. Wahl, 2014, Mammalian target of rapamycin promotes oligodendrocyte differentiation, initiation and extent of CNS myelination, J. Neurosci., 34, 4453, 10.1523/JNEUROSCI.4311-13.2014 · DOI
  105. Norrmén, 2014, mTORC1 controls PNS myelination along the mTORC1-RXRgamma-SREBP-lipid biosynthesis axis in Schwann cells, Cell Rep., 9, 646, 10.1016/j.celrep.2014.09.001 · DOI
  106. Bercury, 2014, Conditional ablation of raptor or rictor has differential impact on oligodendrocyte differentiation and CNS myelination, J. Neurosci., 34, 4466, 10.1523/JNEUROSCI.4314-13.2014 · DOI
  107. Lebrun-Julien, 2014, Balanced mTORC1 activity in oligodendrocytes is required for accurate CNS myelination, J. Neurosci., 34, 8432, 10.1523/JNEUROSCI.1105-14.2014 · DOI
  108. Dai, 2014, Interaction of mTOR and Erk1/2 signaling to regulate oligodendrocyte differentiation, Glia, 62, 2096, 10.1002/glia.22729 · DOI
  109. Khandker, 2022, Cholesterol biosynthesis defines oligodendrocyte precursor heterogeneity between brain and spinal cord, Cell Rep., 38, 10.1016/j.celrep.2022.110423 · DOI
  110. Zou, 2014, Oligodendrocyte precursor cell-intrinsic effect of Rheb1 controls differentiation and mediates mTORC1-dependent myelination in brain, J. Neurosci., 34, 15764, 10.1523/JNEUROSCI.2267-14.2014 · DOI
  111. Carson, 2015, Hypomyelination following deletion of Tsc2 in oligodendrocyte precursors, Ann. Clin. Transl. Neurol., 2, 1041, 10.1002/acn3.254 · DOI
  112. Shi, 2018, mTORC1 activation by loss of Tsc1 in myelinating glia causes downregulation of quaking and neurofascin 155 leading to paranodal domain disorganization, Front. Cell. Neurosci., 12, 201, 10.3389/fncel.2018.00201 · DOI
  113. Ercan, 2017, Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis complex, J. Exp. Med., 214, 681, 10.1084/jem.20160446 · DOI
  114. Lewis, 2013, Impaired language pathways in tuberous sclerosis complex patients with autism spectrum disorders, Cerebr. Cortex, 23, 1526, 10.1093/cercor/bhs135 · DOI
  115. Peters, 2013, Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions, Future Neurol., 8, 583, 10.2217/fnl.13.37 · DOI
  116. Ruppe, 2014, Developmental brain abnormalities in tuberous sclerosis complex: a comparative tissue analysis of cortical tubers and perituberal cortex, Epilepsia, 55, 539, 10.1111/epi.12545 · DOI
  117. Feng, 2010, The star family member QKI and cell signaling, Adv. Exp. Med. Biol., 693, 25, 10.1007/978-1-4419-7005-3_2 · DOI
  118. Larocque, 2005, QUAKING KH domain proteins as regulators of glial cell fate and myelination, RNA Biol., 2, 37, 10.4161/rna.2.2.1603 · DOI
  119. Sidman, 1964, Mutant mice (quaking and jimpy) with deficient myelination in the central nervous system, Science, 144, 309, 10.1126/science.144.3616.309 · DOI
  120. Ebersole, 1996, The quaking gene product necessary in embryogenesis and myelination combines features of RNA binding and signal transduction proteins, Nat. Genet., 12, 260, 10.1038/ng0396-260 · DOI
  121. Darbelli, 2016, Quaking regulates neurofascin 155 expression for myelin and axoglial junction maintenance, J. Neurosci., 36, 4106, 10.1523/JNEUROSCI.3529-15.2016 · DOI
  122. Larocque, 2002, Nuclear retention of MBP mRNAs in the quaking viable mice, Neuron, 36, 815, 10.1016/S0896-6273(02)01055-3 · DOI
  123. Li, 2000, Destabilization and mislocalization of myelin basic protein mRNAs in quaking dysmyelination lacking the QKI RNA-binding proteins, J. Neurosci., 20, 4944, 10.1523/JNEUROSCI.20-13-04944.2000 · DOI
  124. Aberg, 2006, Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia, Proc. Natl. Acad. Sci. USA, 103, 7482, 10.1073/pnas.0601213103 · DOI · Paper page
  125. Lavon, 2019, QKI-V5 is downregulated in CNS inflammatory demyelinating diseases, Mult. Scler. Relat. Disord., 39
  126. Richard, 2010, Reaching for the stars: linking RNA binding proteins to diseases, Adv. Exp. Med. Biol., 693, 142, 10.1007/978-1-4419-7005-3_10 · DOI
  127. Tripathi, 2017, Remarkable stability of myelinating oligodendrocytes in mice, Cell Rep., 21, 316, 10.1016/j.celrep.2017.09.050 · DOI
  128. Lüders, 2019, Maintenance of high proteolipid protein level in adult central nervous system myelin is required to preserve the integrity of myelin and axons, Glia, 67, 634, 10.1002/glia.23549 · DOI
  129. Fornasiero, 2018, Precisely measured protein lifetimes in the mouse brain reveal differences across tissues and subcellular fractions, Nat. Commun., 9, 4230, 10.1038/s41467-018-06519-0 · DOI
  130. Lin, 2014, Impaired eukaryotic translation initiation factor 2B activity specifically in oligodendrocytes reproduces the pathology of vanishing white matter disease in mice, J. Neurosci., 34, 12182, 10.1523/JNEUROSCI.1373-14.2014 · DOI
  131. Ando, 2003, Turnover of myelin lipids in aging brain, Neurochem. Res., 28, 5, 10.1023/A:1021635826032 · DOI
  132. Clarke, 2019, The Ormdl genes regulate the sphingolipid synthesis pathway to ensure proper myelination and neurologic function in mice, Elife, 8, 10.7554/eLife.51067 · DOI
  133. Viader, 2013, Aberrant Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy, Neuron, 77, 886, 10.1016/j.neuron.2013.01.012 · DOI
  134. Beirowski, 2014, Metabolic regulator LKB1 is crucial for Schwann cell-mediated axon maintenance, Nat. Neurosci., 17, 1351, 10.1038/nn.3809 · DOI
  135. Moser, 2005, Adrenoleukodystrophy: new approaches to a neurodegenerative disease, JAMA, 294, 3131, 10.1001/jama.294.24.3131 · DOI · Paper page
  136. Ferdinandusse, 2006, Clinical and biochemical spectrum of D-bifunctional protein deficiency, Ann. Neurol., 59, 92, 10.1002/ana.20702 · DOI
  137. Horvath, 2015, SCP2 mutations and neurodegeneration with brain iron accumulation, Neurology, 85, 1909, 10.1212/WNL.0000000000002157 · DOI
  138. Chung, 2020, Loss- or gain-of-function mutations in ACOX1 cause axonal loss via different mechanisms, Neuron, 106, 589, 10.1016/j.neuron.2020.02.021 · DOI · Paper page
  139. Huyghe, 2006, Peroxisomal multifunctional protein-2 deficiency causes motor deficits and glial lesions in the adult central nervous system, Am. J. Pathol., 168, 1321, 10.2353/ajpath.2006.041220 · DOI
  140. Bams-Mengerink, 2006, MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata, Neurology, 66, 798, 10.1212/01.wnl.0000205594.34647.d0 · DOI · Paper page
  141. Sztriha, 2000, Abnormal myelin formation in rhizomelic chondrodysplasia punctata type 2 (DHAPAT-deficiency), Dev. Med. Child Neurol., 42, 492
  142. Wanders, 2005, Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders, Clin. Genet., 67, 107, 10.1111/j.1399-0004.2004.00329.x · DOI
  143. Waterham, 2012, Genetics and molecular basis of human peroxisome biogenesis disorders, Biochim. Biophys. Acta, 1822, 1430, 10.1016/j.bbadis.2012.04.006 · DOI
  144. Barøy, 2015, A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform, Hum. Mol. Genet., 24, 5845, 10.1093/hmg/ddv305 · DOI · Paper page
  145. Buchert, 2014, A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency, Am. J. Hum. Genet., 95, 602, 10.1016/j.ajhg.2014.10.003 · DOI · Paper page
  146. Ferdinandusse, 2021, An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids, Genet. Med., 23, 740, 10.1038/s41436-020-01027-3 · DOI
  147. Ahmed, 2017, A mutation of EPT1 (SELENOI) underlies a new disorder of Kennedy pathway phospholipid biosynthesis, Brain, 140, 547
  148. Horibata, 2018, EPT1 (selenoprotein I) is critical for the neural development and maintenance of plasmalogen in humans, J. Lipid Res., 59, 1015, 10.1194/jlr.P081620 · DOI
  149. Vaz, 2019, Mutations in PCYT2 disrupt etherlipid biosynthesis and cause a complex hereditary spastic paraplegia, Brain, 142, 3382, 10.1093/brain/awz291 · DOI
  150. Kryukov, 2003, Characterization of mammalian selenoproteomes, Science, 300, 1439, 10.1126/science.1083516 · DOI
  151. Nakashima, 1997, Cloning of a human cDNA for CTP-phosphoethanolamine cytidylyltransferase by complementation in vivo of a yeast mutant, J. Biol. Chem., 272, 9567, 10.1074/jbc.272.14.9567 · DOI
  152. Edvardson, 2008, Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia, Am. J. Hum. Genet., 83, 643, 10.1016/j.ajhg.2008.10.010 · DOI
  153. Kruer, 2010, Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA), Ann. Neurol., 68, 611, 10.1002/ana.22122 · DOI
  154. Kitamura, 2017, Phytosphingosine degradation pathway includes fatty acid alpha-oxidation reactions in the endoplasmic reticulum, Proc. Natl. Acad. Sci. USA, 114, E2616, 10.1073/pnas.1700138114 · DOI
  155. Staps, 2020, Disturbed brain ether lipid metabolism and histology in Sjogren-Larsson syndrome, J. Inherit. Metab. Dis., 43, 1265, 10.1002/jimd.12275 · DOI
  156. Karsai, 2019, DEGS1-associated aberrant sphingolipid metabolism impairs nervous system function in humans, J. Clin. Invest., 129, 1229, 10.1172/JCI124159 · DOI
  157. Pant, 2019, Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy, J. Clin. Invest., 129, 1240, 10.1172/JCI123959 · DOI
  158. Mahmood, 2010, Metachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature, J. Child Neurol., 25, 572, 10.1177/0883073809341669 · DOI
  159. Komatsuzaki, 2019, Clinical characteristics of 248 patients with Krabbe disease: quantitative natural history modeling based on published cases, Genet. Med., 21, 2208, 10.1038/s41436-019-0480-7 · DOI
  160. Wenger, 2000, Krabbe disease: genetic aspects and progress toward therapy, Mol. Genet. Metabol., 70, 1, 10.1006/mgme.2000.2990 · DOI
  161. Pareyson, 2017, New developments in Charcot-Marie-Tooth neuropathy and related diseases, Curr. Opin. Neurol., 30, 471, 10.1097/WCO.0000000000000474 · DOI
  162. Rossor, 2013, Clinical implications of genetic advances in Charcot-Marie-Tooth disease, Nat. Rev. Neurol., 9, 562, 10.1038/nrneurol.2013.179 · DOI
  163. Barreto, 2016, Epidemiologic study of charcot-marie-tooth disease: a systematic review, Neuroepidemiology, 46, 157, 10.1159/000443706 · DOI
  164. Berger, 2006, Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease), Glia, 54, 243, 10.1002/glia.20386 · DOI
  165. Murakami, 2019, Schwann cell and the pathogenesis of charcot-marie-tooth disease, Adv. Exp. Med. Biol., 1190, 301, 10.1007/978-981-32-9636-7_19 · DOI
  166. Fledrich, 2012, A rat model of Charcot-Marie-Tooth disease 1A recapitulates disease variability and supplies biomarkers of axonal loss in patients, Brain, 135, 72, 10.1093/brain/awr322 · DOI
  167. Fledrich, 2018, Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy, Nat. Commun., 9, 3025, 10.1038/s41467-018-05420-0 · DOI
  168. Visigalli, 2020, Exploiting sphingo- and glycerophospholipid impairment to select effective drugs and biomarkers for CMT1A, Front. Neurol., 11, 903, 10.3389/fneur.2020.00903 · DOI
  169. Zhou, 2019, A neutral lipid-enriched diet improves myelination and alleviates peripheral nerve pathology in neuropathic mice, Exp. Neurol., 321, 10.1016/j.expneurol.2019.113031 · DOI
  170. Lee, 2014, PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts, J. Neurosci., 34, 16140, 10.1523/JNEUROSCI.1908-14.2014 · DOI
  171. Zhou, 2020, Subcellular diversion of cholesterol by gain- and loss-of-function mutations in PMP22, Glia, 68, 2300, 10.1002/glia.23840 · DOI
  172. Simons, 2002, Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease, J. Cell Biol., 157, 327, 10.1083/jcb.200110138 · DOI · Paper page
  173. Saher, 2012, Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet, Nat. Med., 18, 1130, 10.1038/nm.2833 · DOI · Paper page
  174. de Faria, 2021, Periods of synchronized myelin changes shape brain function and plasticity, Nat. Neurosci., 24, 1508, 10.1038/s41593-021-00917-2 · DOI
  175. Svennerholm, 1991, Membrane lipids in the aging human brain, J. Neurochem., 56, 2051, 10.1111/j.1471-4159.1991.tb03466.x · DOI
  176. Cheng, 2010, Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease, Neurobiol. Aging, 31, 1188, 10.1016/j.neurobiolaging.2008.07.020 · DOI · Paper page
  177. Han, 2001, Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry, J. Neurochem., 77, 1168, 10.1046/j.1471-4159.2001.00332.x · DOI
  178. Kaya, 2020, Brain region-specific amyloid plaque-associated myelin lipid loss, APOE deposition and disruption of the myelin sheath in familial Alzheimer's disease mice, J. Neurochem., 154, 84, 10.1111/jnc.14999 · DOI
  179. Bartzokis, 2003, White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study, Arch. Neurol., 60, 393, 10.1001/archneur.60.3.393 · DOI
  180. Ringman, 2007, Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations, Brain, 130, 1767, 10.1093/brain/awm102 · DOI · Paper page
  181. Luo, 2019, Application of T1-/T2-weighted ratio mapping to elucidate intracortical demyelination process in the alzheimer's disease continuum, Front. Neurosci., 13, 904, 10.3389/fnins.2019.00904 · DOI
  182. Mitew, 2010, Focal demyelination in Alzheimer's disease and transgenic mouse models, Acta Neuropathol., 119, 567, 10.1007/s00401-010-0657-2 · DOI · Paper page
  183. Mathys, 2019, Single-cell transcriptomic analysis of Alzheimer's disease, Nature, 570, 332, 10.1038/s41586-019-1195-2 · DOI · Paper page
  184. Zhou, 2020, Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease, Nat. Med., 26, 131, 10.1038/s41591-019-0695-9 · DOI · Paper page
  185. Berghoff, 2017, Dietary cholesterol promotes repair of demyelinated lesions in the adult brain, Nat. Commun., 8, 10.1038/ncomms14241 · DOI · Paper page
  186. Stumpf, 2019, Ketogenic diet ameliorates axonal defects and promotes myelination in Pelizaeus-Merzbacher disease, Acta Neuropathol., 138, 147, 10.1007/s00401-019-01985-2 · DOI
  187. Raas, 2021, Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy, J. Clin. Invest., 131, 10.1172/JCI142500 · DOI
  188. Hill, 2018, Lifelong cortical myelin plasticity and age-related degeneration in the live mammalian brain, Nat. Neurosci., 21, 683, 10.1038/s41593-018-0120-6 · DOI · Paper page
  189. Lamming, 2013, Rapalogs and mTOR inhibitors as anti-aging therapeutics, J. Clin. Invest., 123, 980, 10.1172/JCI64099 · DOI · Paper page
  190. Watkins, 1995, Distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies, Ann. Neurol., 38, 472, 10.1002/ana.410380322 · DOI
  191. Ferdinandusse, 2006, Mutational spectrum of D-bifunctional protein deficiency and structure-based genotype-phenotype analysis, Am. J. Hum. Genet., 78, 112, 10.1086/498880 · DOI · Paper page
  192. Schaumburg, 1975, Adrenoleukodystrophy. A clinical and pathological study of 17 cases, Arch. Neurol., 32, 577, 10.1001/archneur.1975.00490510033001 · DOI · Paper page
  193. Dick, 2008, A novel locus for an autosomal recessive hereditary spastic paraplegia (SPG35) maps to 16q21-q23, Neurology, 71, 248, 10.1212/01.wnl.0000319610.29522.8a · DOI
  194. Lossos, 2006, Phenotypic variability among adult siblings with Sjogren-Larsson syndrome, Arch. Neurol., 63, 278, 10.1001/archneur.63.2.278 · DOI
  195. Sjogren, 1957, Oligophrenia in combination with congenital ichthyosis and spastic disorders; a clinical and genetic study, Acta Psychiatr. Neurol. Scand. Suppl., 113, 1
  196. Willemsen, 2000, Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjogren-Larsson syndrome, Am. J. Ophthalmol., 130, 782, 10.1016/S0002-9394(00)00576-6 · DOI
  197. MacFaul, 1982, Metachromatic leucodystrophy: review of 38 cases, Arch. Dis. Child., 57, 168, 10.1136/adc.57.3.168 · DOI
  198. Zafeiriou, 1999, Neurophysiology and MRI in late-infantile metachromatic leukodystrophy, Pediatr. Neurol., 21, 843, 10.1016/S0887-8994(99)00093-4 · DOI
  199. Dolgin, 2019, DEGS1 variant causes neurological disorder, Eur. J. Hum. Genet., 27, 1668, 10.1038/s41431-019-0444-z · DOI
  200. Anstey, 1999, Characterization of photosensitivity in the Smith-Lemli-Opitz syndrome: a new congenital photosensitivity syndrome, Br. J. Dermatol., 141, 406, 10.1046/j.1365-2133.1999.03032.x · DOI

200 of 204 shown

Cited by

Sorted by citations

See all 73

Metadata

Authors
Barnes-Vélez, J. A., Aksoy Yasar, F. B., & Hu, J.
Venue
The Innovation
Publisher
Elsevier BV
Published
2023-01
Volume
4
Issue
1
Pages
100360
ISSN
2666-6758
DOI
10.1016/j.xinn.2022.100360
PMC
PMC9800635
Cited by
73
References
26
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review